Detalhe da pesquisa
1.
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Blood
; 136(24): 2812-2823, 2020 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32730593
2.
Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome.
Proc Natl Acad Sci U S A
; 116(2): 695-700, 2019 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30584089
3.
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood
; 133(7): 676-687, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510081
4.
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
Nature
; 523(7559): 183-188, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26131937
5.
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).
Haematologica
; 99(6): 1041-9, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24682512
6.
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Ann Hematol
; 93(1): 1-11, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24018623
7.
Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA.
Exp Hematol
; 98: 47-52.e6, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794295
8.
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Nat Commun
; 12(1): 2607, 2021 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33972549
9.
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Lancet Haematol
; 7(4): e309-e319, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32145771
10.
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Eur J Cancer
; 108: 120-128, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30654297
11.
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Leukemia
; 33(11): 2575-2584, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30967620
12.
Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity.
Endocrinology
; 149(10): 4809-20, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18556351
13.
The JAMM motif of human deubiquitinase Poh1 is essential for cell viability.
Mol Cancer Ther
; 6(1): 262-8, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17237285
14.
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
Leukemia
; 32(12): 2546-2557, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30275526
15.
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
Cancer Discov
; 8(12): 1540-1547, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355724
16.
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
Leukemia
; 36(3): 869-872, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34743189
17.
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.
Leukemia
; 35(3): 897-900, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32661294
18.
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
J Clin Oncol
; 34(25): 2988-96, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27354480
19.
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
PLoS One
; 10(8): e0135520, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26296092
20.
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
J Clin Oncol
; 29(18): 2521-7, 2011 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21576646